



Agenda

Advisory Panel on the
Assessment of Prevention,
Diagnosis, and Treatment
Options

Fall 2016 Meeting

November 16, 2016
8:00 AM – 4:00 PM ET

8:00 AM – 8:45 AM

Welcome, Introductions, Overview of the Agenda and Meeting Objectives

Yen-pin Chiang, PhD

Program Director, Patient-Centered Outcomes Research Institute

Margaret F. Clayton, PhD, APRN

Chair, Panel on the Assessment of Options

8:45 AM

Conflict of Interest Disclosure Forms

Jayne P. Jordan, *Special Assistant to the General Counsel*

8:50 AM – 9:20 AM

Background and Status of Previous Topics

Stanley Ip, MD

Associate Director, Patient-Centered Outcomes Research Institute

David Hickam, MD, MPH

Program Director, Patient-Centered Outcomes Research Institute

9:20 AM

BREAK I

9:30 AM – 10:45 AM

Review Topic 1

Treatments including watchful waiting for patients with asymptomatic bacteriuria

Expert: Geeta Sood [JHU]

PCORI Lead: Stanley Ip, MD

Advisory Panel Lead: Daniel Wall, BS

11:00 AM – 12:00 PM

Review Topic 2

Treatments of patients with non-muscle invasive bladder cancer

Expert: David Buckley, MD, MPH [OHSU]

PCORI Lead: Stanley Ip, MD

Advisory Panel Lead: Angie Smith, MD, MS

12:00 PM – 12:45 PM

LUNCH

12:45 PM – 1:45 PM

Review Topic 3

Comparative effectiveness of treatments of patients with pancreatic ductal adenocarcinoma (PDAC) and its subtypes

Expert: Remy Coeytaux, MD, PhD [Duke]

PCORI Lead: Sarah Daugherty, PhD, MPH

Advisory Panel Lead: Felix Fernandez, MD, MSc

1:45 PM – 2:00 PM

BREAK II

2:00 PM – 3:00 PM

Review Topic 4

Comparative effectiveness of molecularly directed therapies in patients with lung, pancreas, or bladder cancer

Expert: Brian Wilkerson [ECRI]

PCORI Lead: Danielle Whicher, PhD, MHS

Advisory Panel Lead: Margaret Clayton, PhD, APRN

3:00 PM

Announcements/Final thoughts

4:05 PM

Adjourn